89bio Inc

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. It has a collaboration agreement with Northway Biotechpharma and BiBo Biopharma Engineering Co., Ltd. for the supply of pegozafermin. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.